guest ::
| Home > Publications database > Feasibility of Direct Vitrectomy-Sparing Subretinal Injection for Gene Delivery in Large Animals. > print |
| Home > Publications database > Feasibility of Direct Vitrectomy-Sparing Subretinal Injection for Gene Delivery in Large Animals. > print |
| 001 | 289899 | ||
| 005 | 20240718151627.0 | ||
| 024 | 7 | _ | |a 10.1080/02713683.2024.2343335 |2 doi |
| 024 | 7 | _ | |a pmid:38666493 |2 pmid |
| 024 | 7 | _ | |a 0271-3683 |2 ISSN |
| 024 | 7 | _ | |a 1460-2202 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2024-00891 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Stranak, Zbynek |b 0 |
| 245 | _ | _ | |a Feasibility of Direct Vitrectomy-Sparing Subretinal Injection for Gene Delivery in Large Animals. |
| 260 | _ | _ | |a Abingdon |c 2024 |b Taylor & Francis Group |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1721308553_2265 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2024 Aug;49(8):879-887 |
| 520 | _ | _ | |a To assess the safety and feasibility of direct vitrectomy-sparing subretinal injection for gene delivery in a large animal model.The experimental Liběchov minipigs were used for subretinal delivery of a plasmid DNA vector (pS/MAR-CMV-copGFP) with cytomegalovirus (CMV) promoter, green fluorescent protein (GFP) reporter (copGFP) and a scaffold/matrix attachment region (S/MAR) sequence. The eyes were randomized to subretinal injection of the vector following pars plana vitrectomy (control group) or a direct injection without prior vitrectomy surgery (experimental group). Intra- and post-operative observations up to 30 days after surgery were compared.Six eyes of three mini-pigs underwent surgery for delivery into the subretinal space. Two eyes in the control group were operated with a classical approach (lens-sparing vitrectomy and posterior hyaloid detachment). The other four eyes in the experimental group were injected directly with a subretinal cannula without vitrectomy surgery. No adverse events, such as endophthalmitis, retinal detachment and intraocular pressure elevation were observed post-operatively. The eyes in the experimental group had both shorter surgical time and recovery while achieving the same surgical goal.This pilot study demonstrates that successful subretinal delivery of gene therapy vectors is achievable using a direct injection without prior vitrectomy surgery. |
| 536 | _ | _ | |a 314 - Immunologie und Krebs (POF4-314) |0 G:(DE-HGF)POF4-314 |c POF4-314 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Subretinal injection |2 Other |
| 650 | _ | 7 | |a large animal |2 Other |
| 650 | _ | 7 | |a non-viral gene vector |2 Other |
| 650 | _ | 7 | |a pars plana vitrectomy |2 Other |
| 650 | _ | 7 | |a safety |2 Other |
| 700 | 1 | _ | |a Ardan, Taras |b 1 |
| 700 | 1 | _ | |a Nemesh, Yaroslav |b 2 |
| 700 | 1 | _ | |a Toms, Maria |b 3 |
| 700 | 1 | _ | |a Toualbi, Lyes |b 4 |
| 700 | 1 | _ | |a Harbottle, Richard |0 P:(DE-He78)15dff5647002b4dcfe892b251cd14b62 |b 5 |u dkfz |
| 700 | 1 | _ | |a Ellederova, Zdenka |b 6 |
| 700 | 1 | _ | |a Lytvynchuk, Lyubomyr |b 7 |
| 700 | 1 | _ | |a Petrovski, Goran |b 8 |
| 700 | 1 | _ | |a Motlik, Jan |b 9 |
| 700 | 1 | _ | |a Moosajee, Mariya |b 10 |
| 700 | 1 | _ | |a Kozak, Igor |b 11 |
| 773 | _ | _ | |a 10.1080/02713683.2024.2343335 |g p. 1 - 9 |0 PERI:(DE-600)1483048-6 |n 8 |p 879-887 |t Current eye research |v 49 |y 2024 |x 0271-3683 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:289899 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)15dff5647002b4dcfe892b251cd14b62 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-314 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Immunologie und Krebs |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2023-10-21 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CURR EYE RES : 2022 |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-21 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-21 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-21 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2023-10-21 |
| 920 | 1 | _ | |0 I:(DE-He78)D420-20160331 |k D420 |l DNA-Vektoren |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)F160-20160331 |k F160 |l DNA-Vektoren |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)D420-20160331 |
| 980 | _ | _ | |a I:(DE-He78)F160-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|